What is Synapse Medicine?
Synapse Medicine operates at the intersection of clinical pharmacology and artificial intelligence. Its core offering, a Medication Intelligence platform, is designed to optimize drug utilization and improve patient safety outcomes. By collaborating closely with major French university hospitals, the startup has developed a robust, data-driven ecosystem that assists healthcare professionals in navigating complex medication regimens. The platform serves as a critical tool for reducing adverse drug events and ensuring that clinical decision-making is supported by real-time, evidence-based intelligence. This market position is bolstered by a unique blend of deep clinical integration and scalable software architecture, making it a cornerstone of modern digital health transformation.
How much funding has Synapse Medicine raised?
Synapse Medicine has raised a total of $35.8M across 2 funding rounds:
Series A
$8M
Series B
$27.8M
Series A (2020): $8M with participation from Macsf, XAnge, Nicolas Dessaigne, BNP Paribas, and Bpifrance
Series B (2022): $27.8M led by Macsf, XAnge, BNP Paribas Développement, Mutuelles Impact, and Korelya Capital
Key Investors in Synapse Medicine
Macsf
MACSF is the leading mutual insurance provider for healthcare professionals in France, offering comprehensive financial protection and support services tailored to the medical community.
XAnge
XAnge is a prominent European early-stage venture capital firm that provides both capital and strategic expertise to help visionary founders scale their startups from Seed to Series B.
BNP Paribas Développement
BNP Paribas Développement is a dedicated investment arm of the BNP Paribas group, focusing on long-term equity support for innovative SMEs and high-potential startups.
What's next for Synapse Medicine?
With the successful closure of its latest funding round, Synapse Medicine is set to prioritize the international scaling of its Medication Intelligence technology. The strategic roadmap includes deepening its integration with existing hospital networks while exploring new markets where medication safety remains a high-priority challenge. The company will likely focus on enhancing its algorithmic capabilities to support more complex therapeutic areas, thereby increasing its value proposition for large-scale healthcare providers. As it continues to mature, the firm is expected to leverage its strong investor base—which includes major financial institutions and specialized healthcare insurers—to navigate the regulatory complexities of global expansion and solidify its status as a leader in the digital health landscape.
See full Synapse Medicine company page
